Galmed Pharmaceuticals Ltd. (GLMD)
NASDAQ: GLMD · Real-Time Price · USD
1.580
-0.030 (-1.86%)
At close: Oct 7, 2025, 4:00 PM EDT
1.571
-0.009 (-0.59%)
After-hours: Oct 7, 2025, 7:19 PM EDT

Galmed Pharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202015 - 2019
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Net Income
-8.72-7.52-6.91-17.87-32.47-28.77
Upgrade
Depreciation & Amortization
-0.080.030.040.040.04
Upgrade
Loss (Gain) From Sale of Investments
1.661.140.030.520.08-0.44
Upgrade
Stock-Based Compensation
0.450.530.891.31.892.07
Upgrade
Other Operating Activities
0.580.61-0.31-0.040.01-0.25
Upgrade
Change in Accounts Receivable
-0.3-0.190.350.3-0.310.02
Upgrade
Change in Accounts Payable
0.17-0.57-0.68-2.31-2.181.05
Upgrade
Change in Other Net Operating Assets
0.70.040.47-0.440.040.01
Upgrade
Operating Cash Flow
-5.47-5.88-6.14-18.5-32.89-26.29
Upgrade
Capital Expenditures
----0-0.01-0.04
Upgrade
Investment in Securities
-7.49-0.860.817.5711.4716.58
Upgrade
Other Investing Activities
-0.25-0.25---0-
Upgrade
Investing Cash Flow
-7.74-1.110.817.5611.4616.54
Upgrade
Issuance of Common Stock
16.348.796.190.0717.370.77
Upgrade
Financing Cash Flow
16.348.796.190.0717.370.77
Upgrade
Net Cash Flow
3.131.80.85-0.87-4.06-8.98
Upgrade
Free Cash Flow
-5.47-5.88-6.14-18.51-32.9-26.33
Upgrade
Free Cash Flow Per Share
-2.68-6.32-26.59-132.48-240.78-222.72
Upgrade
Levered Free Cash Flow
-3.76-4.42-3.63-12.16-21.08-15.93
Upgrade
Unlevered Free Cash Flow
-3.38-4.04-3.63-12.16-21.08-15.93
Upgrade
Change in Working Capital
0.57-0.730.13-2.45-2.451.07
Upgrade
Updated Aug 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q